Equities

Beijing Tong Ren Tang Chinese Medicine Co Ltd

Beijing Tong Ren Tang Chinese Medicine Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)7.59
  • Today's Change0.07 / 0.93%
  • Shares traded1.00m
  • 1 Year change-40.24%
  • Beta0.7332
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in HKD

The 2 analysts offering 12 month price targets for Beijing Tong Ren Tang Chinese Medicine have a median target of 12.05, with a high estimate of 12.80 and a low estimate of 11.30. The median estimate represents a 58.76% increase from the last price of 7.59.
High68.6%12.80
Med58.8%12.05
Low48.9%11.30

Dividends

In 2023, Beijing Tong Ren Tang Chinese Medicine Co Ltd reported a dividend of 0.33 HKD, equaling last years dividend. The 2 analysts covering the company expect dividends of 0.34 HKD for the upcoming fiscal year, an increase of 3.03%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in HKD

Beijing Tong Ren Tang Chinese Medicine reported annual 2023 earnings of 0.65 per share on Mar 14, 2024.
Average growth rate+0.17%
More ▼

Revenue history & estimates in HKD

Beijing Tong Ren Tang Chinese Medicine Company Limited had revenues for the full year 2023 of 1.52bn. This was 11.91% below the prior year's results.
Average growth rate+2.36%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.